Search the Newsreel

GLADSTONE LAND CORP 6.00% Cumulative Redeemable Preferred Stock Series B (LANDO.US) will release its earnings report after market close on August 11.

Gladstone Land Corp's 6.00% Cumulative Redeemable Preferred Stock Series B (LANDO.US) is scheduled to release its earnings report. The announcement will occur after the market closes on August 11.

Gladstone Land Corporation (LAND) Stock Price, News, Quote & History

This article provides a detailed overview of Gladstone Land Corporation (LAND), a real estate investment trust specializing in farmland. It covers the company's stock performance, key financial metrics, recent news, analyst ratings, and comparative data with similar companies. The company owns approximately 99,000 acres …

Genmab A/S (GMAB) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Earnings To Watch: Genmab AS (GMAB) Q2 2026 -- GF Value Sees 47% Upside

Mitchells & Butlers (LON:MAB) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell?

Certain Warrants of AgomAb Therapeutics NV are subject to a Lock-Up Agreement Ending on 5-AUG-2026.

Certain warrants of AgomAb Therapeutics NV are under a lock-up agreement set to expire on August 5, 2026. These warrants will be locked up for a period of 181 days, beginning February 5, 2026. The agreement applies to directors, executive officers, and substantially all …

AgomAb Therapeutics (Nasdaq:AGMB) - Stock Analysis

This article provides a stock analysis of AgomAb Therapeutics (AGMB), a clinical-stage biopharmaceutical company. It highlights the company's financial

Gladstone Land (LAND) Projected to Post Earnings on Tuesday

Gladstone Land (NASDAQ:LAND) is expected to report its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts forecasting a loss of $0.2633 per share and revenue of $12.2830 million. The company's shares are trading near their 12-month low, and it recently …

Alphamab Oncology Announces Acceptance of NDA for Anbenitamab as Neoadjuvant Treatment for Her2+ Breast Cancer by the NMPA

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC

How Investors Are Reacting To Genmab (CPSE:GMAB) Epcoritamab’s Phase 3 Overall-Survival Miss in DLBCL

Genmab's epcoritamab Phase 3 trial for diffuse large B-cell lymphoma (DLBCL) did not meet its primary overall survival endpoint in the US, impacting the drug's investment narrative for this indication. However, the drug, now branded as TEPKINLY, recently received European approval for follicular lymphoma, …

Hemab Therapeutics (NASDAQ:COAG) Trading Down 4.8% - What's Next?

CMMB Financials

This article provides a detailed financial overview of Chemomab Therapeutics Ltd (CMMB), including its latest stock price, market capitalization, and P/E ratio. It presents a comprehensive look at the company's income statement, balance sheet, and cash flow statement, offering quarterly and annual data for …

Genmab (CPSE:GMAB) Could Be 22% Below Fair Value On EPCORE Trial Update

Genmab (CPSE:GMAB) is currently valued at DKK1,858.5, which is 22.3% below its fair value of DKK2,392.08, despite the recent news that its Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its primary endpoint for overall survival in the U.S. The company's recent …

Earnings Preview: Genmab to Report Financial Results on August 06

This article provides a preview of Genmab's upcoming financial results, which are scheduled to be reported on August 06. It anticipates that the report will include key financial metrics and potentially an outlook from the company.

Enterprise value to revenue forward of AgomAb Therapeutics NV – NASDAQ:AGMB

This article focuses on the enterprise value to revenue forward of AgomAb Therapeutics NV (NASDAQ:AGMB). It provides a high-level overview of the company's financials as presented on TradingView. The content itself is very minimal, serving more as a title for a financial data point …

Nordic Earnings Week Kicks Off With Novo Nordisk In Focus

The Nordic earnings season is commencing, with pharmaceutical giant Novo Nordisk set to report its Q2 results on August 5th, and Genmab following on August 6th. The timing of these releases—before market open for Novo Nordisk and after close for Genmab—will influence how their …

Genmab A/S (GMAB) Institutional Confidence

Genmab A/S (GMAB) has an institutional shareholding score of 3.00, placing it 192nd among 384 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 13.72% quarter-over-quarter to 12.10%. James Simons is the largest institutional shareholder, holding 0.72% of outstanding …

Genmab A/S (GMAB) Projected to Announce Earnings on Thursday

Genmab A/S (GMAB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Genmab A/S (GMAB), noting its current valuation score of 9.22, ranking it 48th in the Biotechnology & Medical Research industry. The company's P/E ratio is 21.48, which is slightly below its recent high but significantly above its …

Price to sales forward of AgomAb Therapeutics NV – NASDAQ:AGMB

This article provides a brief snapshot of AgomAb Therapeutics NV's (NASDAQ: AGMB) "Price to sales forward" metric. It appears to be a financial data point from TradingView, indicating a period value, change, and percentage change. The article focuses on presenting this specific financial data …

Genmab A/S (GMAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Genmab A/S (GMAB), focusing on its support and resistance levels, various technical indicators, and moving averages. While the stock's price momentum score is low within its industry, its current trading range suggests suitability for range-bound swing trading. …

Chemomab Therapeutics Ltd (CMMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Chemomab Therapeutics Ltd (CMMB) stock, focusing on various indicators and moving averages. It presents a summary of buy, sell, and neutral signals from indicators such as MACD, RSI, and TRIX, alongside moving averages like MA5 and MA10. …

Genmab's DARZALEX royalties boost H1 sales to $8.17B, signaling strong full-year growth potential.

Genmab reported strong first-half results, with DARZALEX sales reaching $8.17 billion, already exceeding half of its $16 billion full-year target. If second-half sales remain consistent, the company is on track to surpass its full-year guidance with total projected sales of $16.59 billion, further boosted …

Genmab's H1 Preview: Darzalex Beats The Sales Outlook

Mitchells & Butlers (LON:MAB) Stock Price Passes Above Two Hundred Day Moving Average - Here's Why

Mitchells & Butlers (LSE:MAB): Why Is Market Interest Rising?

GMAB|Genmab A/S|Price:28.805|Chg%:-0.065

This article provides a comprehensive stock analysis of Genmab A/S (GMAB) highlighting its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite positive analyst ratings and a forecasted upward trend, the technicals currently suggest a sideways trading …

Chemomab Therapeutics Ltd (CMMB) Institutional Confidence

This article provides details on the institutional confidence in Chemomab Therapeutics Ltd (CMMB), including its stock performance and key shareholder activities. It lists several institutional and individual shareholders, along with the shares they hold and their percentage change. The stock closed at $1.410 with …

Chemomab Therapeutics Ltd

This article provides an overview of Chemomab Therapeutics Ltd (CMMB) stock performance, showing a closing price of $1.360 with a -2.86% change. It highlights that critical revenue breakdown data by business segments and regions have not yet been disclosed by the company. The page …

Chemomab Therapeutics Ltd (CMMB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Chemomab Therapeutics Ltd (CMMB). It notes that no dividends have been distributed over the past five years, but lists several stock splits, including a 4:1 merger in August 2025 and multiple 16:1 mergers in …

Chemomab Therapeutics Ltd (CMMB) Valuation: PE, PB & Fair Value Analysis

This article provides a brief valuation analysis for Chemomab Therapeutics Ltd (CMMB), noting key financial metrics. As of the close on July 24th, CMMB had a market cap of $39.17 million and a P/E TTM of 7.81. However, specific P/E, P/B, and P/CF data …

Chemomab Therapeutics Ltd (CMMB) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Chemomab Therapeutics Ltd (CMMB), focusing on volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return Best/Worst Daily Return, Sharpe Ratio, Skewness, Realised Volatility, Standardised True Range, Downside …

Gladstone Land: Why A Dividend Cut Is Likely (NASDAQ:LAND)

Gladstone Land (LAND) faces significant challenges including rising operating expenses, dividend coverage issues, and tenant concentration risks, leading to a revised 'Hold' rating. The company's shift to crop-share agreements has increased exposure to agricultural trends and seasonality, further stressing its adjusted funds from operations …

Chemomab Therapeutics Ltd. Revenue Breakdown – NASDAQ:CMMB

This article provides financial information for Chemomab Therapeutics Ltd. (NASDAQ: CMMB) on TradingView. It indicates that the market is closed with no recent trades. The content focuses on an overview of financial data, segments, and other fundamental statistics for the company.

AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its …